The FDA has approved a new radiopharmaceutical agent to assist in detecting causes of cognitive impairment other than Alzheimer's disease. But unique features of imaging information obtained with florbetapir F18 injection require careful consideration in diagnosis.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: